[
  {
    "ts": null,
    "headline": "Amgen (NasdaqGS:AMGN) Reports Strong Q1 Earnings With Revenue Increase To US$8 Billion",
    "summary": "Amgen (NasdaqGS:AMGN) recently reported strong financial results for Q1 2025, showing a turnaround from a loss to a substantial net income. This positive performance included ambitious revenue and earnings guidance for the year, likely adding weight to the broader market's upward trend, as reflected in a 1.41% price increase. The expansion of the company's manufacturing capabilities and stable share buyback updates may have further supported investor confidence. During this time, broader...",
    "url": "https://finnhub.io/api/news?id=f9bad7255a32b42434b55764a581f9902725868318aa5dcd9e174e023794f22b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746206856,
      "headline": "Amgen (NasdaqGS:AMGN) Reports Strong Q1 Earnings With Revenue Increase To US$8 Billion",
      "id": 134204453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NasdaqGS:AMGN) recently reported strong financial results for Q1 2025, showing a turnaround from a loss to a substantial net income. This positive performance included ambitious revenue and earnings guidance for the year, likely adding weight to the broader market's upward trend, as reflected in a 1.41% price increase. The expansion of the company's manufacturing capabilities and stable share buyback updates may have further supported investor confidence. During this time, broader...",
      "url": "https://finnhub.io/api/news?id=f9bad7255a32b42434b55764a581f9902725868318aa5dcd9e174e023794f22b"
    }
  },
  {
    "ts": null,
    "headline": "Amgen’s Stelara biosimilar gets off to fast start",
    "summary": "Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in revenue for Amgen's biosimilar business.",
    "url": "https://finnhub.io/api/news?id=fca621a481266f13625a6bcec5124b25b0cc6ac539374ffb034cc5c359ae3ab0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746188160,
      "headline": "Amgen’s Stelara biosimilar gets off to fast start",
      "id": 134204454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in revenue for Amgen's biosimilar business.",
      "url": "https://finnhub.io/api/news?id=fca621a481266f13625a6bcec5124b25b0cc6ac539374ffb034cc5c359ae3ab0"
    }
  },
  {
    "ts": null,
    "headline": "Q1 2025 Amgen Inc Earnings Call",
    "summary": "Q1 2025 Amgen Inc Earnings Call",
    "url": "https://finnhub.io/api/news?id=976b1d426b842430b2e6b9ec3fac2e25f020f87fada802a159f7a736370d7d49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746188067,
      "headline": "Q1 2025 Amgen Inc Earnings Call",
      "id": 134184908,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Q1 2025 Amgen Inc Earnings Call",
      "url": "https://finnhub.io/api/news?id=976b1d426b842430b2e6b9ec3fac2e25f020f87fada802a159f7a736370d7d49"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why.",
    "summary": "Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why.",
    "url": "https://finnhub.io/api/news?id=5228d131e48790275e29f239abee84e0342442deac859d64ec7020b4ffffb687",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746186780,
      "headline": "Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why.",
      "id": 134188290,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why.",
      "url": "https://finnhub.io/api/news?id=5228d131e48790275e29f239abee84e0342442deac859d64ec7020b4ffffb687"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth",
    "summary": "AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.",
    "url": "https://finnhub.io/api/news?id=80522095ce252a29cc45acc2b0f967333dc7f7894e04226984ceea0629e7c910",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746186600,
      "headline": "Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth",
      "id": 134184909,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.",
      "url": "https://finnhub.io/api/news?id=80522095ce252a29cc45acc2b0f967333dc7f7894e04226984ceea0629e7c910"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc (AMGN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Pricing Challenges",
    "summary": "Amgen Inc (AMGN) reports a robust 9% revenue increase driven by key brands, despite facing pricing pressures and strategic challenges.",
    "url": "https://finnhub.io/api/news?id=7da6e38fa717cf649a27b9c06ed4332a080877e6c3923ebf9de510e3cd83ddc8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746170143,
      "headline": "Amgen Inc (AMGN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Pricing Challenges",
      "id": 134184910,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc (AMGN) reports a robust 9% revenue increase driven by key brands, despite facing pricing pressures and strategic challenges.",
      "url": "https://finnhub.io/api/news?id=7da6e38fa717cf649a27b9c06ed4332a080877e6c3923ebf9de510e3cd83ddc8"
    }
  }
]